Moderin LA 40 mg/ml 5 ml
Ist die Registrierungsnummer Ihres Landes nicht sichtbar? Dann handelt es sich um ein Kaskadenprodukt. Klicken Sie hier für weitere Informationen.
Auf Lager
MODERIN LA 40 mg/ml suspension for injection for dogs and cats.
Deep intramuscular
Moderin LA 40 mg/ml 5 ml
- Orthopedic and inflammatory disorders of the musculoskeletal system, especially muscles, joints, skeleton, caused by trauma, rheumatism.
- In addition to the treatment of conditions such as arthritis, synovitis, myositis and tendonitis;
- Toxic infectious conditions, especially treatment of acute infections in combination with specific antimicrobial therapy;
- Allergic disorders of the respiratory tract, in particular bronchial asthma;
- Allergic dermal conditions in particular dermatitis, urticaria.
Gebrauchsanweisung
Dosage:
Intramuscular (dog and cat): 0.5-2.0 mg methylprednisolone acetate per kg body weight (corresponding to 0.0125-0.05 ml product / kg body weight); administer deeply intra-muscularly: the dosage depends on the size of the animal and the severity of the condition. In general a single injection is sufficient. Any repetition of the injection should take place according to the benefit / risk assessment of the responsible veterinarian.
intra-articular (dog): 20 mg methylprednisolone acetate in large joints. For smaller ones
joints, a proportionately lower dose is required.
Shelf life of the veterinary medicinal product as packaged for sale: 5 years.
Shelf life after first opening the bottle: 28 days
Methylprednisolone acetate 40 mg.
Tierärztlicher Hinweis
In supportive therapy in severe acute infections in combination with specific targeted bactericidal antimicrobial treatment, the length of the corticosteroid treatment in this indication should generally be limited to a few days. The anti-inflammatory treatment inhibits the immune system and promotes the spread of infectious organisms throughout the body, which can lead to a fulminant infection. At the same time, corticosteroids suppress the fever (signaling function) if this infection becomes systemic. Initial administration of corticosteroids may be beneficial in suppressing the acute symptoms of the disease process.
Co-administration of barbiturates, phenylbutazone, phenytoin or rifampicin may increase the metabolism of the corticosteroids and reduce their effect. The response to anti-coagulants can be reduced by corticosteroids. Combination of glucocorticoids with salicylates and non-steroidal anti-inflammatory agents increases the risk of gastrointestinal complications. Combination of glucocorticoids with thiazide diuretics increases the risk of glucose intolerance.
